Opening & introduction – Dr. Mosaad Morsi, RAY CEO / Dr. Gihan El-Sisi, Managing Director, HTA Office LLC, MENA

Market access role changes over time – Dr. Fawaz Aljand, Value & Access Manager, Amgen KSA

Health Economics: now required than before – Dr. Gihan El-Sisi, Managing Director, HTA Office LLC, MENA

Using Anonymized EMR data to develop RWD real time cohort models – Douglas Drake, Senior Director, Customer Solutions, Clinerion

Dr. Mosaad Morsi

Dr. Mosaad Morsi is an accomplished member of the pharmaceutical industry in the Middle East region, with a wealth of experience in clinical research, medical affairs, and regulatory affairs.

He has held several directorial positions at leading pharmaceutical organizations, including medical and regulatory affairs director at Sanofi-Egypt for 10 years, and the medical director and clinical research director positions at Pfizer-Middle East for 13 years.

By holding these positions, he has developed a comprehensive understanding of the standards imposed by both local and international regulatory bodies.

Dr. Mosaad Morsi has also successfully managed numerous clinical studies at different phases of drug development, overseeing the prompt completion of trials in full compliance with ethical and quality standards.

Gihan Hamdy Elsisi, Msc, PhD

Gihan Hamdy Elsisi, Msc, PhD is Managing Director, HTA Office LLC, MENA and Lecturer, Faculty of Pharmacy, Future University, Arab Academy for Science and Technology & Cairo University. She is the founder and former Head of Pharmacoeconomic Unit at the Central Administration for Pharmaceutical Affairs (CAPA), Egyptian Ministry of Health and former lecturer at Faculty of Pharmacy, German University in Cairo. Elsisi received PhD in Pharmacoeconomics / pharmaceutical sciences from Ain Shams University and certified in Health Economics (HE) and Outcomes Research, University of Washington. Through the CAPA, Elsisi was able to successfully incorporate Pharmacoeconomics and Outcomes Research into the coverage decisions of drugs. She is the principal author of both Health Care Systems Roadmap for Pharmaceutical pricing and reimbursement and the Pharmacoeconomic Guidelines for Egypt, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). She is an executive member in HE Diploma Committee, American University in Cairo. In 2011 and 2012 she received ISPOR awards at the ISPOR 14th and 15th Annual European Congresses in Madrid and Berlin. Elsisi represented Egypt in the First and Second Middle East Africa Pricing & Reimbursement Future Trends Workshop in Muscat 2012 and in Dubai 2013. She has several publications in HE and also contributed to a number of clinical research and surveys. She is the treasurer of ISPOR Egypt Chapter.  She is a special guest speaker at many international companies for achieving market access and maximizing commercial performance in Turkey & Middle East.

The founder and former Head of Pharmacoeconomic Unit at the Central Administration for Pharmaceutical Affairs (CAPA), Egyptian Ministry of Health and former lecturer at Faculty of Pharmacy, German University in Cairo. She received PhD in Pharmacoeconomics / pharmaceutical sciences from Ain Shams University and had got a certificate on Health Economics at the University of Washington. Through the CAPA, she was able to successfully incorporate Pharmacoeconomics into the coverage decisions of drugs. She is the principal author of both Health Care Systems Roadmap for Pharmaceutical pricing and reimbursement and the Pharmacoeconomic Guidelines for Egypt, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). In 2011 and 2012, she received ISPOR awards at the ISPOR 14th and 15th Annual European Congresses. She represented Egypt in the First and Second Middle East Africa Pricing & Reimbursement Future Trends Workshops. She has several publications and also contributed to a number of clinical research and surveys.

Dr. Fawaz Aljand

Dr. Fawaz Aljand is Value & Access Manager, Amgen KSA. He started his career with Abbott in 2002 as Medical Representative, and was promoted to different roles in Sales and Key Account Management and was promoted in 2012 to new role in Market Access. In 2016, he moved to Amgen as Strategic Access manager, and is currently in Value, Access & Policy with different roles in health economics, HTA, model adaptation and tendering process. He holds a B.Sc. Pharmacy 2001.

Dr. Aljand is an expert in Health Economics and Market Access with ongoing Masters in Pharmaco-Economics and Health Management at the University Pompeu Fabra Barcelona, Barcelona School of Management, since 2019. Additionally, he has HTA-Egypt fellowship 2019, PMi Certified 2019, Digital Marketing 2019, Ongoing MBA, UoP USA, 2021.

Douglas Drake, MS, MBA

Douglas Drake is Senior Director, Customer Solutions, at Clinerion. He is originally a life science researcher with a passion for digital enablement of better patient care. For over 30 years, Douglas has worked in various aspects of diagnostics, therapeutic research, drug discovery and global business development. He has broad experience in transformative technologies, data sciences, digital healthcare and applying these to improving patient engagement and the patient journey.